#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Are We There Yet? The Smallpox Research Agenda Using Variola Virus


article has not abstract


Vyšlo v časopise: Are We There Yet? The Smallpox Research Agenda Using Variola Virus. PLoS Pathog 10(5): e32767. doi:10.1371/journal.ppat.1004108
Kategorie: Opinion
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004108

Souhrn

article has not abstract


Zdroje

1. Institute of Medicine (2009) Live Variola Virus: Considerations for Continuing Research. Washington (D.C.): The National Academies Press. Available: http://www.iom.edu/Reports/2009/LiveVariolaVirusContinuingResearch.aspx. Accessed: 26 March 2014.

2. WHO (2010) Scientific review of variola virus research, 1999–2010. Available: http://www.who.int/csr/disease/smallpox/major_review/en/. Accessed: 26 March 2014

3. ReedKD, MelskiJW, GrahamMB, RegneryRL, SotirMJ, et al. (2004) The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 350: 342–350.

4. LiY, OlsonVA, LaueT, LakerMT, DamonIK (2006) Detection of monkeypox virus with real-time PCR assays. J Clin Virol 36: 194–203.

5. Quixabeira-SantosJC, MedagliaML, PescadorCA, DamasoCR (2011) Animal movement and establishment of vaccinia virus cantagalo strain in Amazon biome, Brazil. Emerg Infect Dis 17: 726–729.

6. DabrowskiPW, RadonicA, KurthA, NitscheA (2013) Genome-wide comparison of cowpox viruses reveals a new clade related to variola virus. PLoS One 8: e79953.

7. MoussatcheN, DamasoCR, McFaddenG (2008) When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond. J Infect Dev Ctries 2: 156–173.

8. PrichardMN, KernER (2012) Orthopoxvirus targets for the development of new antiviral agents. Antiviral Res 94: 111–125.

9. YangG, PevearDC, DaviesMH, CollettMS, BaileyT, et al. (2005) An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 79: 13139–13149.

10. ParkerS, TouchetteE, OberleC, AlmondM, RobertsonA, et al. (2008) Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 77: 39–49.

11. MuckerEM, GoffAJ, ShamblinJD, GrosenbachDW, DamonIK, et al. (2013) Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob Agents Chemother 57: 6246–6253.

12. VoraS, DamonI, FulginitiV, WeberSG, KahanaM, et al. (2008) Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 46: 1555–1561.

13. LedermanER, DavidsonW, GroffHL, SmithSK, WarkentienT, et al. (2012) Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 206: 1372–1385.

14. KretzschmarM, WallingaJ, TeunisP, XingS, MikolajczykR (2006) Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med 3: e272.

15. MonathTP, CaldwellJR, MundtW, FuscoJ, JohnsonCS, et al. (2004) ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)–a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8 Suppl 2: S31–44.

16. KennedyJS, GurwithM, DekkerCL, FreySE, EdwardsKM, et al. (2011) Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis 204: 1395–1402.

17. GreenbergRN, OvertonET, HaasDW, FrankI, GoldmanM, et al. (2013) Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis 207: 749–758.

18. FreySE, WinokurPL, SalataRA, El-KamarySS, TurleyCB, et al. (2013) Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario. Vaccine 31: 3025–3033.

19. KennedyRB, OvsyannikovaI, PolandGA (2009) Smallpox vaccines for biodefense. Vaccine 27 Suppl 4: D73–79.

20. DamonIK, DavidsonWB, HughesCM, OlsonVA, SmithSK, et al. (2009) Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 90: 1962–1966.

21. ShchelkunovSN (2013) An increasing danger of zoonotic orthopoxvirus infections. PLoS Pathog 9: e1003756.

22. SmeeDF, SidwellRW, KefauverD, BrayM, HugginsJW (2002) Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 46: 1329–1335.

23. SmeeDF, WanderseeMK, BaileyKW, HostetlerKY, HolyA, et al. (2005) Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir Chem Chemother 16: 203–211.

24. JacksonRJ, RamsayAJ, ChristensenCD, BeatonS, HallDF, et al. (2001) Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 75: 1205–1210.

25. McFaddenG (2010) Killing a killer: what next for smallpox? PLoS Pathog 6: e1000727.

26. CannJA, JahrlingPB, HensleyLE, Wahl-JensenV (2013) Comparative pathology of smallpox and monkeypox in man and macaques. J Comp Pathol 148: 6–21.

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2014 Číslo 5
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Získaná hemofilie - Povědomí o nemoci a její diagnostika
nový kurz

Eozinofilní granulomatóza s polyangiitidou
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#